Novo’s once-weekly insulin rejected by FDA
Bio Pharma Dive
JULY 11, 2024
The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing.
Let's personalize your content